Severe Congenital Neutropenia–Pulmonary Hypertension–Superficial Venous Angiectasis Syndrome are born baby with very low neutrophils (a key white blood cell), and who also show small surface blood-vessel widenings on the skin (superficial venous angiectasis/telangiectasia), plus high blood pressure in the arteries of the lungs (pulmonary arterial hypertension, PAH). In many reported families, the neutropenia part is caused by mutations in the G6PC3 gene, a known form of severe congenital neutropenia (often called SCN4). Children can have very frequent infections from birth because neutrophils are missing, and some also show visible, dilated surface veins and heart/lung problems that may include PAH. PAH, if present, strains the right side of the heart and can cause breathlessness, fatigue, and swelling. Because this is rare, treatment plans are individualized and may combine infection prevention and neutrophil support (for SCN) with guideline-based PAH therapy. AHA Journals+3NCBI+3malacards.org+3

In G6PC3-related SCN, the same gene problem that blocks neutrophil development can also affect blood-vessel biology and heart structure, producing a “prominent superficial vein pattern,” congenital heart defects, and sometimes pulmonary hypertension. Separately, research in PAH shows that neutrophil enzymes (like neutrophil elastase) are higher than normal and may drive blood-vessel damage, which links the immune system with PAH biology. That means a child with SCN can have both infection risk and lung-artery disease for biologic reasons, not just coincidence. PMC+2BioMed Central+2

• Severe congenital neutropenia (SCN): From birth, the absolute neutrophil count is very low, causing frequent infections (mouth, lungs, skin, liver). Long-term, there’s a small but real risk of bone-marrow problems like MDS/AML, so careful monitoring is needed. Many patients respond well to G-CSF injections that boost neutrophils. NCBI+1

• Pulmonary arterial hypertension (PAH): The small lung arteries are abnormally tight and thick. The right heart must pump harder, leading to breathlessness, faintness, chest pain, ankle swelling, and, in advanced cases, right-sided heart failure if untreated. Treatments target pathways (endothelin, nitric oxide/cGMP, and prostacyclin). AHA Journals

• Superficial venous angiectasis / telangiectasia: These are small, widened blood vessels seen on the skin surface. In G6PC3 deficiency, a “prominent superficial vein pattern” can be part of the syndrome. They are usually cosmetic but can guide clinicians toward the underlying diagnosis. malacards.org+1

This is a rare genetic condition where three things happen together:

1. the body does not make enough mature neutrophils (white blood cells that fight germs),

2. the blood pressure inside the lung arteries becomes too high, and

3. the small surface veins under the skin look unusually wide, many, or prominent (called “venous angiectasis” or a type of venous malformation).

The neutrophil problem is usually present from birth and is called severe congenital neutropenia (SCN). In one well-described form, changes (mutations) in a gene named G6PC3 cause SCN along with body-wide features such as visible superficial veins and sometimes heart-lung problems. Doctors sometimes call that form SCN type 4 or G6PC3 deficiency. In this overlap syndrome, the same child or adult shows SCN, signs of high pressure in lung arteries (pulmonary hypertension), and visible superficial venous angiectasis. Putting them together helps doctors think about the right tests, watch for infections, and pick safe treatments. NCBI+2PMC+2

Pulmonary hypertension (PH) means the mean pressure measured inside the lung arteries is higher than normal by heart-catheter testing. PH has several “groups” based on cause (problems in the lung arteries themselves, in the left heart, from lung diseases and low oxygen, from old clots, and from other rare causes). This grouping guides testing and treatment. OUP Academic+2European Society of Cardiology+2

Superficial venous angiectasis belongs to the family of venous malformations (low-flow vascular malformations) and can appear as prominent, dilated veins on the skin surface. Imaging such as ultrasound or MRI helps confirm it and separate it from other conditions. PMC+2AJR Online+2

---

Other names

• Severe congenital neutropenia (SCN) associated with G6PC3 deficiency (often labeled SCN type 4) NCBI+1

• G6PC3-related congenital neutropenia with prominent superficial veins PMC+1

• Syndromic SCN with cardiovascular anomalies (classic G6PC3 phenotype) NCBI

• Pulmonary arterial hypertension (PAH) or pulmonary hypertension (depending on the exact group found) OUP Academic

• Superficial venous malformation / venous angiectasia (low-flow VM) PMC

---

Types

By the neutropenia component

1. Isolated SCN: only low neutrophils, usually due to genes like ELANE, HAX1, G6PC3, GFI1 and others. NCBI+2Wiley Online Library+2

2. Syndromic SCN (G6PC3): SCN plus other findings such as prominent superficial veins, heart/urogenital anomalies, and sometimes PH. NCBI+1

By the pulmonary hypertension component (clinical “groups”)

1. Group 1 (PAH): disease of the small lung arteries themselves.
2. Group 2: PH due to left heart disease.
3. Group 3: PH due to lung disease and/or low oxygen.
4. Group 4: PH from chronic blood clots (CTEPH).
5. Group 5: PH with unclear or multiple causes. These groups matter because each has a different testing path and treatment plan. OUP Academic+1

By the venous lesion

1. Superficial venous angiectasis (dilated surface veins; low-flow).
2. Mixed venous malformation (if deeper components are present).
3. Localized vs. widespread pattern on the body surface. Ultrasound with Doppler and MRI help define which pattern is present. PMC+1

---

Causes

1. G6PC3 gene mutations: the most characteristic cause joining SCN with prominent superficial veins; can also include heart/lung features that set the stage for PH in some patients. PMC+1

2. Other SCN genes (ELANE, HAX1, GFI1, etc.): mainly cause neutropenia; some individuals may have additional vascular or cardiac findings depending on the gene and modifiers. NCBI+2Wiley Online Library+2

3. Congenital heart defects (e.g., atrial septal defect) associated with G6PC3 or other syndromic SCN; altered blood flow can contribute to PH over time. PMC

4. Chronic or recurrent lung infections due to neutropenia: scarring and low oxygen can drive PH (Group 3). OUP Academic

5. Sleep-related breathing problems or chronic hypoxemia: long-term low oxygen can raise lung artery pressures (Group 3). OUP Academic

6. Chronic thromboembolic disease: repeated clots can cause CTEPH (Group 4). OUP Academic

7. Left-sided heart disease: valve or muscle problems can create backward pressure (Group 2 PH). OUP Academic

8. Inflammation and endothelial stress from recurrent infections: may impair vessel function and widen superficial veins. (Inference grounded in venous malformation biology.) PMC

9. Developmental venous malformation: a structural low-flow vascular malformation present from birth that appears as angiectatic superficial veins. PMC

10. Genetic modifiers of vascular tone in some SCN patients: can influence PH risk and vein appearance. (Inference; supported by variability in syndromic SCN reports.) PMC

11. Autoimmune triggers superimposed on SCN: inflammation can worsen endothelial health and symptoms. (General vascular/PH principle.) OUP Academic

12. Chronic anemia or high-output states increasing cardiac strain, indirectly stressing the lung vessels. (PH physiology background.) OUP Academic

13. Environmental exposures (e.g., biomass smoke, pollutants) that damage lungs and drive Group 3 PH. OUP Academic

14. Unresolved congenital shunts (e.g., unrepaired septal defects) with long-standing increased lung blood flow. PMC

15. Recurrent severe infections in early life: scars and bronchiectasis can form and later support PH. (PH/lung disease link.) OUP Academic

16. Nutritional deficits during growth: poor tissue repair can magnify vascular fragility and infection risk (supporting, not primary cause). (General principle.)

17. Medication complications from repeated antibiotics (rare) leading to secondary organ effects that can aggravate PH drivers (e.g., kidney/liver effects). (General safety principle.)

18. Unrecognized small pulmonary emboli in immobilized or severe infection episodes leading to later CTEPH. OUP Academic

19. Connective tissue or systemic inflammatory overlap in an individual patient (rare) adding extra vascular stress. (General PH Group 5 concept.) AHA Journals

20. Family-level genetic background: explains why some relatives with the same SCN gene show veins and PH while others show mainly neutropenia. (Variability noted in G6PC3 reports.) PMC

---

Symptoms

1. Frequent infections from early infancy (skin, lungs, ears, gums) because neutrophils are very low. Fevers can be high and illnesses can be severe. NCBI+1

2. Mouth ulcers, gum swelling, or persistent gingivitis, often recurring. NCBI

3. Poor wound healing or infections after small cuts. NCBI

4. Shortness of breath on exertion (walking, climbing) due to PH; later even at rest. OUP Academic

5. Fainting or near-fainting with activity (syncope) in advanced PH. OUP Academic

6. Chest discomfort or pressure not explained by coronary disease, related to high strain on the right heart. OUP Academic

7. Swelling of legs or abdomen from right-heart strain if PH becomes advanced. OUP Academic

8. Bluish lips or fingertips (cyanosis) from low oxygen in some PH groups. OUP Academic

9. Visible, prominent superficial veins on trunk or limbs (venous angiectasis). PMC+1

10. Cosmetic concern or tenderness over dilated veins, occasionally with pain on standing if malformations are extensive. PMC

11. Recurrent cough or wheeze, sometimes from repeated chest infections. NCBI

12. Poor growth or low energy during active infections or severe PH. OUP Academic

13. Nosebleeds or easy bruising in some patients with venous lesions or frequent antibiotics (not universal). PMC

14. Palpitations from right-heart strain or low oxygen episodes. OUP Academic

15. Anxiety or reduced exercise tolerance, because breathing and infection worries limit daily life. (Quality-of-life impact noted across PH and SCN.) OUP Academic+1

---

Diagnostic tests

Physical examination (bedside)

1. General exam with temperature and vital signs: checks fever, breathing rate, oxygen level, and heart rate/blood pressure; helps judge infection and cardiopulmonary stress right away. NCBI

2. Skin and mucosa check: looks for ulcers, folliculitis, cellulitis, nail fold infections, and venous patterns on chest, abdomen, or limbs that suggest angiectasis. PMC

3. Heart and lung exam: listens for a loud second heart sound, murmurs, or crackles; these can hint at PH or chronic lung disease. OUP Academic

4. Edema and liver size: ankle swelling and a tender, enlarged liver can suggest right-heart strain from PH. OUP Academic

“Manual” or functional tests (simple, clinic-based)

5. Six-minute walk test (6MWT): measures how far a person walks in six minutes and checks oxygen level changes; useful to track PH severity over time. OUP Academic

6. Orthostatic vein exam and limb elevation test: bedside maneuvers that show how superficial venous angiectasis fills and empties; supports a low-flow venous malformation pattern. PMC

7. Simple infection assessment tools (pain with swallowing, dental tapping, skin pressure): help locate likely infection foci during febrile episodes in SCN. NCBI

8. Pulse oximetry at rest and with walking: detects oxygen drops that may unmask PH or lung disease contributors. OUP Academic

Laboratory and pathological tests

9. Complete blood count (CBC) with differential: shows the absolute neutrophil count (ANC); in SCN the ANC is persistently very low unless treated. Serial CBCs help track stability and response to therapy. NCBI+1

10. Inflammatory markers (CRP/ESR), cultures: identify active infection, guide antibiotics, and document how often infections occur. NCBI

11. Bone marrow aspirate/biopsy: in SCN, the marrow often shows a “maturation arrest” of neutrophil development; this confirms the pattern and excludes other marrow diseases. PMC

12. Genetic testing panel for SCN (e.g., G6PC3, ELANE, HAX1, GFI1 and others): pinpoints the cause, supports counseling, and links to associated features like superficial venous angiectasis in G6PC3 deficiency. NCBI+1

13. BNP/NT-proBNP blood test: cardiac stress markers that can rise when the right heart is under strain in PH; useful for monitoring with other tests. OUP Academic

14. Autoimmune and thrombophilia screening (selected cases): rules out rarer contributors to PH or unusual clotting that might mimic or worsen the condition. OUP Academic

Electrodiagnostic and hemodynamic tests

15. 12-lead electrocardiogram (ECG): looks for right-heart strain, right-axis deviation, or rhythm problems often seen in moderate to severe PH. OUP Academic

16. Right-heart catheterization (RHC): the gold-standard test to confirm PH, measure pulmonary pressures and resistance, and test how blood vessels respond to medications during the procedure. It also helps classify the PH group. OUP Academic+1

Imaging tests

17. Transthoracic echocardiogram (heart ultrasound): estimates pressure in the lung artery, checks right-heart size and function, and screens for congenital heart defects that may drive PH. Often the first imaging step. OUP Academic

18. Chest X-ray and high-resolution CT (HRCT): show lung scarring or bronchiectasis from repeated infections and exclude other lung diseases linked to Group 3 PH. OUP Academic

19. Ventilation–perfusion (V/Q) scan: looks for old or current clots in lung vessels (CTEPH), a key treatable PH cause. OUP Academic

20. Venous ultrasound with Doppler (and sometimes MRI) of the affected body area: confirms superficial venous angiectasis as a low-flow venous malformation, maps the extent, and guides therapy such as compression or sclerotherapy if needed. PMC+1

Non-pharmacological treatments (therapies & other measures)

1. Vaccination with inactivated vaccines (household too)
   What: Keep the child and close contacts up to date with inactivated vaccines (no live vaccines unless specialist approves). Purpose: Reduce preventable infections when neutrophils are low. Mechanism: Trains the immune system safely so exposure to real germs is less likely to cause severe disease. BioMed Central

2. Prompt fever plan (“fever = emergency”)
   What: Written plan to go to hospital quickly if fever occurs. Purpose: Early antibiotics save lives in neutropenia. Mechanism: Rapid treatment before bacteria spread. BioMed Central

3. Oral and dental hygiene program
   What: Daily brushing, flossing, antiseptic mouth rinses, and early treatment of gum sores. Purpose: Prevents mouth infections common in SCN. Mechanism: Lowers bacteria in the mouth that can seed the blood. NCBI

4. Infection-avoidance habits
   What: Handwashing, safe food prep, avoiding raw/undercooked foods, careful wound care. Purpose: Reduce exposure to germs. Mechanism: Removes or kills microbes before they enter the body. BioMed Central

5. Environmental mold and dust control
   What: Keep living spaces dry, fix leaks, use HEPA filtration when advised. Purpose: Less fungal exposure (e.g., Aspergillus). Mechanism: Lowers airborne spores that can cause severe infection when neutropenic. BioMed Central

6. Central line care protocols (if a catheter is present)
   What: Strict sterile technique for line access; chlorhexidine care. Purpose: Prevent bloodstream infections. Mechanism: Blocks bacteria entry via lines. BioMed Central

7. Pulmonary rehabilitation (age-appropriate)
   What: Supervised exercise, breathing training, energy-conservation tips. Purpose: Improves endurance and quality of life in PAH. Mechanism: Trains muscles and breathing efficiency without overstraining the heart. AHA Journals

8. Oxygen therapy (when indicated)
   What: Supplemental oxygen during sleep or activity if saturations fall. Purpose: Relieves hypoxemia to reduce right-heart strain. Mechanism: Increases oxygen delivery; reduces pulmonary vasoconstriction triggered by low oxygen. AHA Journals

9. Salt and fluid guidance for PAH/right-heart strain
   What: Moderate salt, watch fluids per specialist advice. Purpose: Minimize swelling and right-heart workload. Mechanism: Less fluid retention lowers venous pressure. AHA Journals

10. Compression garments for telangiectasia/visible veins (select cases)
    What: Graduated stockings or sleeves. Purpose: Reduce venous pooling, discomfort, and cosmetic prominence. Mechanism: External pressure supports superficial veins. Wikipedia

11. Sun protection / trigger avoidance for facial telangiectasia
    What: Sunscreen, gentle skincare, avoid extreme heat. Purpose: Prevent flare and new vessels. Mechanism: Reduces UV-driven vessel dilation and skin injury. Wikipedia

12. Laser or light therapy for bothersome skin vessels
    What: Vascular lasers in dermatology. Purpose: Cosmetic improvement, occasional bleeding control. Mechanism: Light targets hemoglobin, collapsing abnormal surface vessels. Wikipedia

13. Cardiopulmonary monitoring plan
    What: Scheduled echocardiography, 6-minute walk tests, NT-proBNP. Purpose: Track PAH progression and therapy response. Mechanism: Objective measures guide timely treatment changes. AHA Journals

14. Bone-marrow surveillance
    What: Periodic blood counts, sometimes marrow exams. Purpose: Detect MDS/AML early in long-standing SCN. Mechanism: Finds clonal changes early for timely action. NCBI

15. Antimicrobial prophylaxis protocols (non-drug behaviors included)
    What: In addition to meds when indicated, emphasize household infection control. Purpose: Lower breakthrough infections. Mechanism: Multilayer barrier (behavior + meds when prescribed). BioMed Central

16. Nutritional optimization
    What: Adequate calories, iron, B-vitamins, protein; registered dietitian input. Purpose: Support blood cell production and healing. Mechanism: Supplies substrates for marrow and tissues. BioMed Central

17. Exercise pacing & activity planning
    What: Short, frequent activities; rest between; avoid overexertion. Purpose: Maintain fitness without provoking PAH symptoms. Mechanism: Keeps heart workload within safe limits. AHA Journals

18. Psychosocial support & education
    What: Counseling, support groups, school/work plans. Purpose: Reduce stress, improve adherence. Mechanism: Knowledge and support improve coping and outcomes. BioMed Central

19. Specialist care coordination
    What: Hematology-immunology + pulmonary hypertension center + dermatology. Purpose: Integrate complex care. Mechanism: Multidisciplinary review prevents gaps in treatment. BioMed Central+1

20. Genetic counseling for families
    What: Discuss inheritance, testing siblings/parents. Purpose: Clarify risks and reproductive choices. Mechanism: Identifies carriers and informs early surveillance. NCBI

---

Drug treatments

Important: Dosing is individualized—follow the treating specialist and the current FDA label. Selected labels are cited from accessdata.fda.gov.

1. Filgrastim (G-CSF; NEUPOGEN® and biosimilars)
   Class: Granulocyte colony-stimulating factor. Typical dosing/time: SC daily; titrated to keep ANC safe per hematology. Purpose: Raise neutrophil counts in SCN to prevent infections. Mechanism: Stimulates marrow to produce and release neutrophils. Side effects: Bone pain, splenomegaly; rare splenic rupture; long-term SCN requires monitoring for MDS/AML. Label information for filgrastim supports neutrophil recovery. FDA Access Data+2FDA Access Data+2

2. Pegfilgrastim (NEULASTA®; and pegfilgrastim-fpgk, etc.)
   Class: Long-acting G-CSF. Dosing/time: SC typically once per cycle in oncology; in SCN, hematologists may use individualized schedules. Purpose: Sustained neutrophil support with fewer injections. Mechanism: Pegylation prolongs half-life to maintain ANC. Side effects: Bone pain; rare splenic issues. FDA labels detail use and precautions. FDA Access Data+1

3. Broad-spectrum IV antibiotics for febrile neutropenia (e.g., cefepime, piperacillin-tazobactam, or meropenem)
   Class: Antibacterial agents. Dosing/time: Hospital protocols—start immediately with fever. Purpose: Treat likely bacterial sepsis in neutropenia. Mechanism: Rapid bactericidal activity while cultures pending. Side effects: Allergic reactions, C. difficile risk. (Labels for specific agents are FDA-approved and guide dosing/risks.) BioMed Central

4. Antifungal therapy (e.g., voriconazole, posaconazole, amphotericin B when indicated)
   Class: Antifungals. Dosing/time: Per infectious disease guidelines when fungal infection suspected or proven. Purpose: Cover invasive mold/yeast infections in prolonged neutropenia. Mechanism: Disrupts fungal cell membranes or enzymes. Side effects: Liver toxicity, renal toxicity (amphotericin). (FDA labels detail dosing and monitoring.) BioMed Central

5. Bosentan (TRACLEER®)
   Class: Endothelin receptor antagonist (ERA). Dosing/time: Oral, titrated; requires monthly liver tests and REMS. Purpose: Reduce PAH symptoms and improve exercise capacity. Mechanism: Blocks endothelin-A/B receptors to lower pulmonary vascular resistance. Side effects: Liver enzyme elevation, edema, teratogenicity (strict pregnancy prevention). FDA Access Data+1

6. Ambrisentan (LETAIRIS®)
   Class: ERA. Dosing/time: Oral once daily; REMS with pregnancy testing. Purpose: PAH symptom improvement and delay in clinical worsening. Mechanism: Selective endothelin-A receptor blockade causing vasodilation. Side effects: Fluid retention, teratogenicity. FDA Access Data+1

7. Macitentan (OPSUMIT®)
   Class: ERA. Dosing/time: Oral once daily; REMS. Purpose: Reduce morbidity/mortality events in PAH. Mechanism: Dual endothelin receptor blockade with tissue penetration. Side effects: Anemia, nasopharyngitis, teratogenicity. FDA Access Data+1

8. Sildenafil (REVATIO®)
   Class: PDE-5 inhibitor. Dosing/time: Oral 20 mg three times daily (adult label); pediatric dosing per label/center protocols. Purpose: Improves exercise ability and delays clinical worsening in PAH. Mechanism: Inhibits PDE-5, raises cGMP, relaxes pulmonary vascular smooth muscle. Side effects: Headache, flushing, visual changes; avoid with nitrates. FDA Access Data+1

9. Tadalafil (ADCIRCA®)
   Class: PDE-5 inhibitor. Dosing/time: Oral 40 mg once daily (adults) per label. Purpose: Improves exercise ability in PAH. Mechanism: Sustained PDE-5 inhibition increases cGMP-mediated vasodilation. Side effects: Headache, dyspepsia; avoid with nitrates. FDA Access Data+2FDA Access Data+2

10. Riociguat (ADEMPAS®)
    Class: Soluble guanylate cyclase stimulator. Dosing/time: Oral, titrated; pregnancy REMS. Purpose: Improves 6-minute walk distance and WHO class in PAH. Mechanism: Directly stimulates sGC to boost cGMP independent of nitric oxide. Side effects: Hypotension, headache; contraindicated in pregnancy. FDA Access Data+1

11. Epoprostenol (FLOLAN®/VELETRI®)
    Class: Prostacyclin (PGI2). Dosing/time: Continuous IV infusion via pump and central line; titrate. Purpose: For advanced PAH (NYHA III–IV) to improve exercise capacity and symptoms. Mechanism: Potent vasodilation and antiproliferative effects in pulmonary arteries; antiplatelet action. Side effects: Flushing, jaw pain, catheter infections; abrupt stop can be dangerous. FDA Access Data+1

12. Treprostinil (REMODULIN® / TYVASO® inhaled)
    Class: Prostacyclin analogue. Dosing/time: SC/IV continuous infusion, or inhaled/oral forms per label; careful titration. Purpose: Improve walk distance and symptoms in PAH; allows non-IV options. Mechanism: Prostacyclin-receptor agonism causes vasodilation and anti-remodeling. Side effects: Infusion-site pain (SC), headache; avoid abrupt withdrawal. FDA Access Data+1

13. Iloprost (VENTAVIS®)
    Class: Inhaled prostacyclin analogue. Dosing/time: Multiple inhalations daily per label. Purpose: Symptom relief and functional improvement. Mechanism: Inhaled pulmonary vasodilation targeted to ventilated lung units. Side effects: Cough, flushing, jaw pain. FDA Access Data+1

14. Selexipag (UPTRAVI®)
    Class: Oral IP (prostacyclin) receptor agonist. Dosing/time: Oral, uptitrated in weekly steps as tolerated. Purpose: Reduce PAH disease progression and hospitalization risk. Mechanism: Selective IP receptor activation reduces vascular resistance and remodeling. Side effects: Headache, diarrhea, jaw pain; avoid in severe hepatic impairment. FDA Access Data+1

15. Targeted diuretics (e.g., furosemide) for right-heart failure signs
    Class: Loop diuretic. Dosing/time: Oral/IV as needed for edema under cardiology guidance. Purpose: Control fluid overload from PAH-related right-heart strain. Mechanism: Increases salt/water excretion to reduce venous congestion. Side effects: Low potassium, dizziness. (FDA labels support diuretic indications and cautions.) AHA Journals

16. Iron repletion if iron-deficient
    Class: Iron preparations (oral/IV). Dosing/time: Per labs and guidelines. Purpose: Optimize oxygen delivery and exercise tolerance. Mechanism: Restores hemoglobin formation. Side effects: GI upset (oral), infusion reactions (IV). AHA Journals

17. Prophylactic antibiotics (select patients)
    Class: e.g., oral anti-staphylococcal agents as directed. Dosing/time: Individualized by hematology based on infections. Purpose: Cut recurrence while on G-CSF. Mechanism: Suppresses common pathogens. Side effects: Resistance, C. difficile risk—specialist oversight essential. BioMed Central

18. Antiviral prophylaxis (e.g., acyclovir) when indicated
    Class: Antivirals. Dosing/time: Based on history (e.g., recurrent HSV). Purpose: Prevent viral reactivation during neutropenia. Mechanism: Inhibits viral DNA polymerase. Side effects: Nausea, kidney effects at high doses. (FDA labels provide dosing/risks.) BioMed Central

19. Antifungal prophylaxis (e.g., posaconazole) in prolonged severe neutropenia
    Class: Triazole antifungal. Dosing/time: Per ID/hematology during high-risk periods. Purpose: Prevent invasive molds/yeasts. Mechanism: Ergosterol synthesis inhibition. Side effects: Hepatic enzyme elevation, drug interactions. BioMed Central

20. IVIG (selected cases with hypogammaglobulinemia or recurrent infections)
    Class: Immune globulin. Dosing/time: IV every 3–4 weeks when indicated. Purpose: Replace antibodies to reduce infections. Mechanism: Provides pooled IgG to enhance humoral immunity. Side effects: Headache, infusion reactions. (Use per specialist; FDA-licensed products/labels guide safety.) BioMed Central

Why PAH drugs appear here: PAH is part of the triad. Modern PAH therapy uses any of three pathways—endothelin, nitric oxide/cGMP, prostacyclin—alone or in combination, guided by expert centers. Elevated neutrophil elastase and immune signals in PAH research support biologic plausibility for overlap with neutrophil disorders. Chest Journal

---

Dietary molecular supplements

1. Vitamin C
   Dose (example): 100–200 mg/day food-first; supplement if low. Function: Collagen and wound healing; antioxidant. Mechanism: Supports barrier function and neutrophil oxidative burst; deficiency worsens gum/skin issues. BioMed Central

2. Vitamin D
   Dose: Per level-guided replacement (often 600–2000 IU/day). Function: Immune modulation and bone health. Mechanism: Nuclear receptor effects on innate immunity; low levels are common in chronic illness. BioMed Central

3. Zinc
   Dose: Short courses 10–20 mg elemental/day if deficient. Function: Epithelial repair and immune enzyme function. Mechanism: Cofactor for DNA synthesis and neutrophil enzymes; excess can deplete copper. BioMed Central

4. Folate (B9)
   Dose: 400 mcg/day; higher only if prescribed. Function: DNA synthesis for marrow cells. Mechanism: One-carbon metabolism enables cell division; deficiency impairs hematopoiesis. BioMed Central

5. Vitamin B12
   Dose: As prescribed when low. Function: Myelin and red-cell production. Mechanism: Cofactor for DNA synthesis; corrects megaloblastic changes that can complicate anemia. BioMed Central

6. Iron (if deficient only)
   Dose: Oral or IV per labs. Function: Hemoglobin/oxygen transport. Mechanism: Restores iron-dependent erythropoiesis for better oxygen delivery in PAH. AHA Journals

7. Omega-3 fatty acids (EPA/DHA)
   Dose: ~1 g/day combined EPA/DHA (food-first; supplements per clinician). Function: Anti-inflammatory support. Mechanism: Competes with arachidonic acid pathways to lower inflammatory mediators. AHA Journals

8. Protein/essential amino acids
   Dose: Dietitian-guided (~1.0–1.2 g/kg/day unless restricted). Function: Tissue repair and immune protein synthesis. Mechanism: Provides building blocks for immunoglobulins and enzymes. BioMed Central

9. Selenium
   Dose: 50–100 mcg/day if low. Function: Antioxidant enzymes (glutathione peroxidase). Mechanism: May help redox balance relevant to vascular health. Excess can be toxic. AHA Journals

10. Probiotics/fermented foods (case-by-case)
    Dose: Food-based preferred; supplements only with clinician approval in neutropenia. Function: Gut barrier and microbiome support. Mechanism: Competes with pathogens; avoid in profound neutropenia if risk of bacteremia is a concern. BioMed Central

---

Drugs Immunity-booster / regenerative / stem-cell–directed

1. Granulocyte colony-stimulating factors (G-CSF: filgrastim/pegfilgrastim)
   What/Why: Core regenerative therapy for SCN that “boosts” neutrophil production. Dose: Individualized SC schedules. Function/Mechanism: Drives marrow progenitors toward mature neutrophils via G-CSF receptor signaling. FDA Access Data+1

2. Granulocyte-macrophage CSF (GM-CSF; selected refractory cases)
   What/Why: Considered when G-CSF response is suboptimal. Dose: Specialist-directed. Function/Mechanism: Stimulates broader myeloid lineage; more side effects than G-CSF. BioMed Central

3. Hematopoietic stem cell transplantation (HSCT) conditioning meds (context of HSCT)
   What/Why: Not a “supplement,” but curative intent for refractory SCN/MDS evolution. Function/Mechanism: Replaces defective marrow with donor stem cells to establish normal neutrophil production. NCBI

4. IVIG (immune globulin) in selected immunodeficiency patterns
   What/Why: Reduces infections when antibody levels are low or function is poor. Function/Mechanism: Passive immunity with pooled IgG. BioMed Central

5. Antimicrobial prophylaxis regimens (immune support by infection prevention)
   What/Why: Not truly “regenerative,” but reduces infection burden while marrow is supported. Function/Mechanism: Lowers pathogen load during neutropenia. BioMed Central

6. Elafin (research context; not standard care)
   What/Why: Research has linked PAH to high neutrophil elastase and relative elafin deficiency; therapeutic modulation is investigational. Function/Mechanism: Elastase inhibition might protect pulmonary vessels. Note: Not approved therapy at this time. PubMed

---

Surgeries / procedures

1. Central venous catheter placement
   Why: For continuous IV prostacyclin (epoprostenol) in advanced PAH, and for difficult IV access during infections. Procedure: Sterile insertion of tunneled catheter; requires meticulous care. FDA Access Data

2. Atrial septal defect (ASD) repair (if present)
   Why: Some G6PC3 patients have congenital heart defects; repair can optimize hemodynamics and reduce shunt-related PAH drivers. Procedure: Surgical or device closure based on anatomy. NCBI

3. Lung transplantation (selected end-stage PAH cases)
   Why: For refractory PAH despite maximal therapy. Procedure: Bilateral lung transplant in specialized centers. AHA Journals

4. Hematopoietic stem cell transplantation (HSCT)
   Why: For SCN that is G-CSF-refractory, intolerant, or with evolution to MDS/AML. Procedure: Conditioning chemo, donor stem-cell infusion, long recovery. NCBI

5. Dermatologic laser procedures for telangiectasia
   Why: Cosmetic improvement or to stop recurrent bleeding from surface vessels. Procedure: Targeted vascular laser sessions by dermatology. Wikipedia

---

Preventions

1. Keep a written fever plan and act fast with any fever. BioMed Central

2. Hand hygiene for the whole family and caregivers. BioMed Central

3. Vaccinations with inactivated vaccines; household also vaccinated. BioMed Central

4. Food safety: avoid raw eggs, raw fish, unpasteurized dairy; wash produce well. BioMed Central

5. Dental care every day and regular dentist visits. NCBI

6. Avoid smoking exposure; protect lungs to ease PAH. AHA Journals

7. Avoid pregnancy on ERAs/riociguat; strict REMS rules. FDA Access Data+2FDA Access Data+2

8. Plan activity with rest breaks; avoid sudden overexertion. AHA Journals

9. Home mold/damp control to lower fungal risks. BioMed Central

10. Regular specialist follow-up for blood counts and heart-lung tests. NCBI+1

---

When to see a doctor (or go to emergency)

• Fever (≥38 °C/100.4 °F) at any time—this is an emergency in neutropenia. Go to the hospital now. BioMed Central

• New shortness of breath, chest pain, fainting, blue lips, or fast swelling—urgent PAH evaluation is needed. AHA Journals

• New painful mouth sores, skin abscess, or wound redness—early antibiotics may be needed. NCBI

• Persistent cough or hemoptysis—needs urgent assessment. AHA Journals

• Rapid weight gain, severe ankle/abdominal swelling—could be right-heart strain. AHA Journals

---

What to eat and what to avoid

1. Eat: Well-cooked proteins (eggs, chicken, fish, legumes) for healing and immune proteins. Avoid: Raw/undercooked meats/eggs/sushi. BioMed Central

2. Eat: Pasteurized dairy, yogurt if allowed. Avoid: Unpasteurized milk/cheese. BioMed Central

3. Eat: Washed fruits/vegetables; peel when possible. Avoid: Unwashed produce and salad bars with poor hygiene. BioMed Central

4. Eat: Whole grains for energy and fiber. Avoid: Excess salt if PAH with fluid retention. AHA Journals

5. Eat: Vitamin-rich foods (citrus, berries, leafy greens) to support repair. Avoid: Ultra-processed foods replacing nutrient-dense meals. BioMed Central

6. Hydration: Steady fluids as advised; in PAH with edema, follow the specialist’s fluid plan. AHA Journals

7. Eat: Iron-rich foods (beans, meats) if iron-deficient. Avoid: Self-starting iron without labs. AHA Journals

8. Limit alcohol (adults)—worsens liver function, important with ERAs. FDA Access Data

9. Caffeine in moderation if it worsens palpitations or breathlessness. AHA Journals

10. Food safety habits every day at home. BioMed Central

---

FAQs

1) Is this a known syndrome?
Yes. G6PC3-related severe congenital neutropenia can include prominent superficial veins and congenital heart/lung issues; pulmonary hypertension has been reported in some patients and families. It is very rare and needs expert care. NCBI+1

2) How is severe congenital neutropenia diagnosed?
By blood counts showing very low neutrophils from early life, bone-marrow evaluation, and genetic testing (e.g., G6PC3, ELANE, others) to define the subtype. NCBI

3) Why do infections happen so often?
Neutrophils are the “first responder” white cells. When they are absent, bacteria and fungi spread more easily, causing mouth, skin, and lung infections. BioMed Central

4) How is neutropenia treated day-to-day?
Most patients receive G-CSF injections to raise neutrophils, plus fast antibiotics at any sign of infection and careful dental/skin care. FDA Access Data

5) What is pulmonary arterial hypertension (PAH) and why is it dangerous?
It’s high pressure in lung arteries. The right side of the heart must pump against this load, which can lead to heart failure if untreated. AHA Journals

6) How is PAH treated?
With targeted drugs from three pathways (endothelin receptor antagonists, PDE-5 inhibitors/riociguat, prostacyclin-pathway agents), often in combination at a specialty center. FDA Access Data+2FDA Access Data+2

7) Do neutrophil problems and PAH interact biologically?
Research shows higher neutrophil elastase and lower elafin levels in PAH, suggesting an immune-vascular link; in G6PC3 deficiency, vascular/heart anomalies are part of the phenotype. Chest Journal+1

8) Is there a cure for SCN?
Hematopoietic stem cell transplantation (HSCT) can be curative in selected cases (refractory to G-CSF or with clonal complications), but it carries risks and requires a specialized center. NCBI

9) Can laser help the skin veins?
Yes, for cosmetic reasons or minor bleeding. Vascular lasers can collapse small surface vessels; dermatology will guide type and expectations. Wikipedia

10) What follow-up tests are important?
Regular CBCs (for ANC), periodic marrow checks in long-term SCN, echocardiograms and walk tests for PAH, and liver tests when on ERAs. NCBI+2AHA Journals+2

11) Are these medicines safe in pregnancy?
Several PAH drugs (ERAs, riociguat) are contraindicated in pregnancy due to fetal harm; strict REMS applies. Discuss family planning with your team. FDA Access Data+2FDA Access Data+2

12) What about live vaccines?
Decisions are individualized; in many cases live vaccines are deferred in significant immunodeficiency. Follow specialist guidance. BioMed Central

13) Why do I need dental visits so often?
Gum disease is common in SCN. Early care prevents infections that can spread to the bloodstream. NCBI

14) When should families consider genetic counseling?
Early—because G6PC3-related SCN is typically autosomal recessive and affects recurrence risks, carrier testing, and prenatal options. NCBI

15) Are there research directions?
Yes. Work continues on immune-vascular links (e.g., elastase/elafin axis) and on optimizing combination PAH therapy and long-term SCN outcomes. Ask about registries and clinical trials. Chest Journal+1

Disclaimer: Each person’s journey is unique, treatment plan, life style, food habit, hormonal condition, immune system, chronic disease condition, geological location, weather and previous medical  history is also unique. So always seek the best advice from a qualified medical professional or health care provider before trying any treatments to ensure to find out the best plan for you. This guide is for general information and educational purposes only. Regular check-ups and awareness can help to manage and prevent complications associated with these diseases conditions. If you or someone are suffering from this disease condition bookmark this website or share with someone who might find it useful! Boost your knowledge and stay ahead in your health journey. We always try to ensure that the content is regularly updated to reflect the latest medical research and treatment options. Thank you for giving your valuable time to read the article.

The article is written by Team RxHarun and reviewed by the Rx Editorial Board Members

Last Updated: October 13, 2025.